Physician profile
Jack C Evans
NPI 1396784187
$2,041.89
in general payments reported to CMS, 2019-2025
27 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $156 · 2021: $672 · 2022: $368 · 2023: $384 · 2024: $211 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $739.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $417.90 | 2019-2024 | |
| Lilly USA, LLC | $297.34 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $217.65 | 2020-2025 | |
| Amgen INC. | $174.65 | 2019-2024 | Prolia, Evenity, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.02 | 2019-2022 | |
| Abbott Laboratories | $138.97 | 2021-2023 | Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $69.44 | 2024-2025 | |
| Allergan, INC. | $68.91 | 2019-2020 | |
| Daiichi Sankyo INC. | $60.29 | 2021 | |
| Novartis Pharmaceuticals Corporation | $58.76 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $54.41 | 2023-2025 | Xarelto, Spravato |
| Glaxosmithkline, LLC. | $48.11 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.91 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $27.81 | 2021-2022 | |
| Pfizer INC. | $27.25 | 2021-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $26.59 | 2021-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $23.51 | 2022 | |
| Vertos Medical, INC. | $19.49 | 2024 | Mild Device Kit |
| Shield Therapeutics INC | $19.26 | 2023 | Accrufer |
| Dexcom, INC. | $18.19 | 2021 | |
| Exact Sciences Corporation | $17.57 | 2024 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $13.83 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.30 | 2020 | |
| Supernus Pharmaceuticals, INC. | $13.25 | 2021 | |
| Astellas Pharma US INC | $13.21 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.19 | 2022 | |
| Adlon Therapeutics L.P. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.